Masimo Co. (NASDAQ:MASI) Director Sanford Fitch sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $113.14, for a total transaction of $226,280.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Sanford Fitch also recently made the following trade(s):
- On Monday, October 1st, Sanford Fitch sold 2,000 shares of Masimo stock. The stock was sold at an average price of $124.50, for a total transaction of $249,000.00.
- On Tuesday, September 11th, Sanford Fitch sold 10,000 shares of Masimo stock. The stock was sold at an average price of $118.29, for a total transaction of $1,182,900.00.
- On Tuesday, September 4th, Sanford Fitch sold 2,000 shares of Masimo stock. The stock was sold at an average price of $119.45, for a total transaction of $238,900.00.
MASI stock traded down $1.68 during midday trading on Friday, reaching $111.35. 760,800 shares of the company’s stock traded hands, compared to its average volume of 523,116. The stock has a market cap of $5.98 billion, a price-to-earnings ratio of 45.45, a price-to-earnings-growth ratio of 2.70 and a beta of 1.01. Masimo Co. has a fifty-two week low of $80.69 and a fifty-two week high of $126.89.
Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.02. The firm had revenue of $210.58 million for the quarter, compared to analysts’ expectations of $207.62 million. Masimo had a net margin of 15.30% and a return on equity of 21.49%. Masimo’s revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.56 earnings per share. On average, research analysts anticipate that Masimo Co. will post 2.9 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on MASI shares. Needham & Company LLC started coverage on shares of Masimo in a research report on Friday, September 14th. They issued a “buy” rating on the stock. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 17th. Stifel Nicolaus raised their target price on shares of Masimo from $112.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 2nd. Zacks Investment Research cut shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, August 1st. Finally, Piper Jaffray Companies raised their target price on shares of Masimo to $120.00 and gave the stock a “neutral” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $114.40.
A number of hedge funds have recently made changes to their positions in MASI. FMR LLC lifted its position in Masimo by 6,605.4% during the second quarter. FMR LLC now owns 1,821,994 shares of the medical equipment provider’s stock valued at $177,918,000 after buying an additional 1,794,822 shares in the last quarter. Schroder Investment Management Group lifted its position in Masimo by 77.2% during the second quarter. Schroder Investment Management Group now owns 799,435 shares of the medical equipment provider’s stock valued at $106,225,000 after buying an additional 348,169 shares in the last quarter. Scout Investments Inc. acquired a new position in Masimo during the third quarter valued at approximately $33,793,000. Caisse DE Depot ET Placement DU Quebec acquired a new position in Masimo during the second quarter valued at approximately $21,483,000. Finally, Victory Capital Management Inc. lifted its position in Masimo by 43.4% during the third quarter. Victory Capital Management Inc. now owns 641,074 shares of the medical equipment provider’s stock valued at $79,838,000 after buying an additional 194,055 shares in the last quarter. 82.88% of the stock is currently owned by hedge funds and other institutional investors.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: Bull Market
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.